BioSpace News Archive

Keystone Bio announced today their participation as a keynote speaker at the Sachs 6th Annual Neuroscience Innovation Forum in San Francisco, CA.

AA Medical is pleased to announce it has completed a partnership with Certified Endoscopy Products (“Certified Endoscopy” or “Certified”), a leading Chicago-based medical device reprocessing company specialized in endoscopic devices.

Northwest Biotherapeutics reported positive results of voting at the Annual Shareholders Meeting on December 30, 2022 , and discussion at the Meeting (which was publicly available) about achievements in 2022 and anticipated activities in 2023.

2seventy bio, Inc. (Nasdaq: TSVT) today announced an amendment to its collaboration with Regeneron that will facilitate an expanded and accelerated development plan for novel cell therapy-based combinations for solid tumors.

Longeveron Inc. today provided a corporate update highlighting the Company’s strategic priorities and anticipated milestones for 2023.

American CryoStem Corporation (OTC Pink: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies that powers its clinical pipeline, announced today that it has received U.S. Food and Drug Administration (FDA) approval to proceed with a Phase I Clinical Trial for the treatment of Long COVID/PASC.

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company " or “Marvel "), are pleased to announce that it has successfully completed a multi-kilogram scale run under current good manufacturing practices (“cGMP”) of the active pharmaceutical ingredient (API) of the Company’s lead asset MB-204

The team of Battelle, AmplifyBio and Andelyn Biosciences has won a seat on an eight-year, $149 million indefinite delivery, indefinite quantity (IDIQ) contract vehicle for the National Institute of Neurological Disorders and Stroke.

Gemina Laboratories Ltd. is pleased to announce the completion of its influenza A/B rapid test prototype.

Legacy Healthcare, a clinical-stage biopharmaceutical company today announced positive results from the RAAINBOW phase 2/3 randomized placebo-controlled trial evaluating Coacillium 22.25% cutaneous solution in children and adolescents with moderate and severe alopecia areata, a debilitating autoimmune condition causing disfiguring scalp hair loss.